title: Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
abstract: OBJECTIVE
  Neuroendocrine differentiation is a frequent pattern in prostate adenocarcinoma. CgA seems to be a useful indicator of neuroendocrine differentiation in patients with HRPC. We evaluated the clinical interest of circulating CgA in HRPC.
  
  
  METHODS
  Serum CgA was assessed by immunoradiometric assay in 39 patients with HRPC treated with paclitaxel and carboplatin or mitoxantrone. Baseline CgA and its variation during chemotherapy were studied.
  
  
  RESULTS
  Increased serum CgA was observed in 45% of patients. Previous local radiotherapy and the duration of hormonal therapy were independent factors that influenced CgA. There was no correlation between CgA and prostate specific antigen. Increased serum CgA showed positive predictive significance but no prognostic value. The chemotherapy response correlated with a CgA decrease of greater than 25%.
  
  
  CONCLUSIONS
  The current study suggests that CgA assessment facilitates patient selection by predicting the chemotherapy response and providing complementary information to follow the chemotherapy response.
authors.affiliation: Centre Jean Perrin, Clermont-Ferrand, France; UMR484 INSERM, Clermont-Ferrand, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Cabrespine
authors.forename: Laurent
authors.initials: L
authors.lastname: Guy
authors.forename: Françoise
authors.initials: F
authors.lastname: Gachon
authors.forename: Hervé
authors.initials: H
authors.lastname: Curé
authors.forename: Philippe
authors.initials: P
authors.lastname: Chollet
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D016190:Carboplatin / Q000627:therapeutic use*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D016190:Carboplatin; D008942:Mitoxantrone; D017239:Paclitaxel